title: How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient?
authors.affiliation: Division of Otolaryngology, George Washington University, Washington, DC, U.S.A.
authors.forename: Nitin J
authors.initials: NJ
authors.lastname: Patel
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Bauman
mesh_terms: D000284:Administration, Oral; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D005500:Follow-Up Studies; D018324:Hemangioma, Capillary / Q000151:congenital / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007297:Inpatients / Q000706:statistics & numerical data; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods; D010045:Outpatients / Q000706:statistics & numerical data; D011433:Propranolol / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000151:congenital / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D011433:Propranolol